Acknowledgement
이 연구는 국민건강보험 일산병원의 연구비 지원으로 이루어졌음 (NHIMC2018CR014).
References
- Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731-41.
- Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-6. https://doi.org/10.1007/s00198-004-1713-3
- Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-76. https://doi.org/10.1210/jcem.85.9.6818
- Magnus KK, Karl JO, Per OJ. Osteoporotic fractures. In: Robert WB, James DH, Charles CB, ed. Rockwood and Green's fractures in adults. 6th ed. Philadelphia: Lippincott-Raven; 2005. 209-56.
- Yang KH. Anti-osteoporotic drugs and fracture healing mechanism. J Korean Fract Soc. 2011;24:212-6. https://doi.org/10.12671/jkfs.2011.24.2.212
- Fracture and dislocation compendium. Orthopaedic Trauma Association Committee for coding and classification. J Orthop Trauma. 1996;10 Suppl 1:v-ix, 1-154.
- Fogagnolo F, Kfuri M Jr, Paccola CA. Intramedullary fixation of pertrochanteric hip fractures with the short AO-ASIF proximal femoral nail. Arch Orthop Trauma Surg. 2004;124:31-7. https://doi.org/10.1007/s00402-003-0586-9
- Almeida M, O'Brien CA. Basic biology of skeletal aging: role of stress response pathways. J Gerontol A Biol Sci Med Sci. 2013;68:1197-208. https://doi.org/10.1093/gerona/glt079
- Suk SI. Orthopaedics. 7th ed. Seoul: New Medical Publishing Co.; 2013. 1440-62.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. https://doi.org/10.1056/NEJM200105103441904
- Nakamura T, Sugimoto T, Nakano T, et al. Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097-106. https://doi.org/10.1210/jc.2011-3479
- Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14:960-8. https://doi.org/10.1359/jbmr.1999.14.6.960
- Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25:404-14. https://doi.org/10.1359/jbmr.090731
- Song HK, Kim SJ, Lee JH, Yang KH. Intermittent parathyroid hormone treatment for stimulation of callus formation in elderly patients. J Korean Fract Soc. 2012;25:295-9. https://doi.org/10.12671/jkfs.2012.25.4.295
- Kanakaris NK, West RM, Giannoudis PV. Enhancement of hip fracture healing in the elderly: evidence deriving from a pilot randomized trial. Injury. 2015;46:1425-8. https://doi.org/10.1016/j.injury.2015.06.033
- Huang TW, Chuang PY, Lin SJ, et al. Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures. Medicine (Baltimore). 2016;95:e3626. https://doi.org/10.1097/md.0000000000003626
- Miyakoshi N, Aizawa T, Sasaki S, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab. 2015;33:553-9. https://doi.org/10.1007/s00774-014-0617-3